Virtu Financial
MBRX icon

Virtu Financial’s Moleculin Biotech MBRX Stock Holding History

Virtu Financial’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-119
Closed -$18K – 1830
2025
Q2 		$18K Buy
+119
New +$48.8K ﹤0.01% 1264
2023
Q2 		– Sell
-2
Closed -$16K – 1817
2023
Q1 		$16K Hold
2
– – ﹤0.01% 1286
2022
Q4 		$15K Buy
+2
New +$16.9K ﹤0.01% 1320
2022
Q1 		– Sell
-6
Closed -$87K – 1800
2021
Q4 		$87K Buy
+6
New +$106K 0.01% 1181
2021
Q3 		– Sell
-3
Closed -$93K – 1771
2021
Q2 		$93K Buy
+3
New +$81.9K 0.01% 1225
2019
Q1 		– Hold
0
– -$13K – 1667
2018
Q4 		– Hold
0
– – – 1418
2018
Q2 		– Hold
0
– -$24K – 2294
2018
Q1 		– Hold
0
– – – 1803
2017
Q4 		– Hold
0
– – – 2185

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRT Financial
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
IEQ Capital
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
Wealth Dimensions Group
Wealth Dimensions Group Cincinnati, Ohio $558M AUM 20.63% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Virtu Financial's MBRX Position: Q3 2025 in Review

Virtu Financial sold out of Moleculin Biotech (MBRX) in Q3 2025, closing a stake of 119 shares — an estimated $18K sold.

Virtu Financial first reported a position in MBRX in Q2 2021 and held it in 5 quarters. The position peaked at $93K in Q2 2021. 20 funds tracked by Wall St. Rank hold MBRX as of Q3 2025.

  • Virtu Financial reported no remaining Moleculin Biotech position as of Q3 2025 after selling out during the quarter.
  • Virtu Financial sold 119 Moleculin Biotech shares in Q3 2025, an estimated $18K.
  • Virtu Financial first reported a position in Moleculin Biotech in Q2 2021 and held it in 5 quarters.
  • Virtu Financial's Moleculin Biotech position peaked at $93K in Q2 2021.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2025.

Based on Virtu Financial's 13F filing for Q3 2025, filed 14 Nov 2025.